Arkolith/Insider Trading/OTLC/Form 4

Trieu Vuong

CHAIRMAN AND CEO, Director, 10% OwnerOncotelic Therapeutics, Inc. (OTLC) · full profile →Form 4 · filed Jun 24, 2026
Net Buying
Open-Market Buys
$11K
Open-Market Sells
$0
Net Open-Market Flow
$11K
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 24, 2026Buy(P)115K$0.04$5K93.9M
Jun 23, 2026Buy(P)75K$0.04$3K93.8M
Jun 22, 2026Buy(P)65K$0.04$3K93.7M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-26-029997) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML